KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Share-based Compensation (2016 - 2026)

Neogenomics filings provide 17 years of Share-based Compensation readings, the most recent being $9.6 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 10.4% to $9.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $40.2 million, a 109.56% increase, with the full-year FY2025 number at $41.3 million, up 23.65% from a year prior.
  • Share-based Compensation hit $9.6 million in Q1 2026 for Neogenomics, up from $8.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.2 million in Q2 2025 to a low of $100000.0 in Q2 2024.
  • Median Share-based Compensation over the past 5 years was $7.9 million (2024), compared with a mean of $7.4 million.
  • Biggest five-year swings in Share-based Compensation: crashed 60.69% in 2023 and later soared 12114.0% in 2025.
  • Neogenomics' Share-based Compensation stood at $4.7 million in 2022, then surged by 49.9% to $7.0 million in 2023, then rose by 19.14% to $8.3 million in 2024, then dropped by 3.43% to $8.0 million in 2025, then grew by 19.82% to $9.6 million in 2026.
  • The last three reported values for Share-based Compensation were $9.6 million (Q1 2026), $8.0 million (Q4 2025), and $10.3 million (Q3 2025) per Business Quant data.